The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A platinum coordination entity with cis square-planar geometry in which platinum(II) is coordinated to two ammonia ligands and a bidentate cyclobutane-1,1-dicarboxylate ligand.
Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased phosphorylation of AKT1 protein]; Carboplatin promotes the reaction [Pulsatilla saponin A inhibits the reaction [1,2-Dimethylhydrazine results in increased phosphorylation of AKT1 protein]]; Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein]; Pulsatilla saponin A promotes the reaction [Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased phosphorylation of AKT1 protein]]
ANXA4 protein results in decreased susceptibility to Carboplatin ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin] Carboplatin affects the localization of ANXA4 protein
Carboplatin affects the localization of ATP7A protein [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]
Carboplatin results in decreased expression of BAX mRNA [Carboplatin co-treated with Gallic Acid] results in increased expression of BAX protein; [Gallic Acid co-treated with Carboplatin] results in increased expression of BAX mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of BAX mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of BAX protein; [Paclitaxel co-treated with Carboplatin] results in increased expression of BAX mRNA; [Paclitaxel co-treated with Carboplatin] results in increased expression of BAX protein; Carboplatin results in increased cleavage of and results in increased expression of BAX protein Carboplatin results in increased expression of BAX mRNA; Carboplatin results in increased expression of BAX protein
Carboplatin results in decreased expression of BCL2L1 protein Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein]
Carboplatin results in decreased expression of BECN1 protein Carboplatin promotes the reaction [Chloroquine results in decreased expression of BECN1 protein]; Chloroquine promotes the reaction [Carboplatin results in decreased expression of BECN1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein]; [Carboplatin co-treated with Gallic Acid] results in increased expression of CASP3 protein; [Gallic Acid co-treated with Carboplatin] results in increased expression of CASP3 mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of CASP3 mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of CASP3 protein; [Paclitaxel co-treated with Carboplatin] results in increased expression of CASP3 mRNA; [Paclitaxel co-treated with Carboplatin] results in increased expression of CASP3 protein; Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein] Carboplatin results in increased expression of CASP3 mRNA; Carboplatin results in increased expression of CASP3 protein [Carboplatin co-treated with 1,2-Dimethylhydrazine] results in increased expression of CASP3 protein; Carboplatin promotes the reaction [[Pulsatilla saponin A co-treated with 1,2-Dimethylhydrazine] results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pulsatilla saponin A promotes the reaction [[Carboplatin co-treated with 1,2-Dimethylhydrazine] results in increased expression of CASP3 protein] Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Carboplatin results in increased activity of CASP7 protein palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]
Carboplatin results in increased activity of CASP9 protein Carboplatin results in increased expression of CASP9 protein Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein] Carboplatin results in decreased expression of CASP9 mRNA
Carboplatin results in decreased activity of CAT protein Carboplatin results in decreased expression of and results in decreased activity of CAT protein Carboplatin results in decreased expression of CAT protein
Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein]; Carboplatin promotes the reaction [Pulsatilla saponin A inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein]]; Pulsatilla saponin A promotes the reaction [Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein]]
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CYCS protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein]
Carboplatin results in increased expression of H2AX protein palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]
HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4] Carboplatin results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased susceptibility to Carboplatin Carboplatin results in increased expression of HMOX1 mRNA
Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein]; Carboplatin promotes the reaction [Pulsatilla saponin A inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein]]; Pulsatilla saponin A promotes the reaction [Carboplatin inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein]]
Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]] Carboplatin results in decreased expression of NFKB1 mRNA
Carboplatin results in decreased phosphorylation of NFKBIA protein NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin]; PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin] Carboplatin results in increased expression of PCNA mRNA
Carboplatin results in decreased expression of PDCD1LG2 STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2]
PTGS2 protein results in decreased susceptibility to Carboplatin wortmannin inhibits the reaction [PTGS2 protein results in decreased susceptibility to Carboplatin]
Carboplatin results in decreased localization of and results in decreased activity of RELA protein; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
SLC31A1 gene mutant form results in decreased susceptibility to Carboplatin SLC31A1 protein results in increased susceptibility to Carboplatin SLC31A1 protein results in increased uptake of Carboplatin SLC31A1 protein results in increased import of Carboplatin [Penicillamine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [Trientine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin
Carboplatin results in decreased expression of and results in decreased activity of SOD1 protein Carboplatin results in decreased expression of SOD1 protein
Carboplatin results in increased expression of and results in increased activity of SOD2 protein Carboplatin results in decreased expression of SOD2 protein
Carboplatin results in increased expression of TP53 mRNA; Carboplatin results in increased expression of TP53 protein [Carboplatin co-treated with Gallic Acid] results in increased expression of TP53 protein; [Gallic Acid co-treated with Carboplatin] results in increased expression of TP53 mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of TP53 mRNA; [Paclitaxel co-treated with Carboplatin co-treated with Gallic Acid] results in increased expression of TP53 protein; [Paclitaxel co-treated with Carboplatin] results in increased expression of TP53 mRNA; [Paclitaxel co-treated with Carboplatin] results in increased expression of TP53 protein